All In Biotech

Investigational drug · Phase 2

SHR-2173

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Generalized Myasthenia Gravis, Active Lupus Nephritis, Primary IgA Nephropathy.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

5

5 still active

All registered trials

9

Any phase or sponsor naming "SHR-2173"

First trial start

2025

Nov 22, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SHR-2173", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Generalized Myasthenia Gravis
  • Active Lupus Nephritis
  • Primary IgA Nephropathy
  • Primary Membranous Nephropathy
  • Systemic Lupus Erythematosus

Approved drugs for the same conditions: Myasthenia gravis · Lupus (SLE) · IgA nephropathy · Neurology · Immunology and inflammation · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "SHR-2173" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Generalized Myasthenia Gravis

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • TelitaciceptRC18, RC18-LPhase 38 trials

    RemeGen Co., Ltd. · CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease

  • IMVT-1402Phase 37 trials

    Immunovant Sciences GmbH · Graves' Disease, Rheumatoid Arthritis, Subacute Cutaneous Lupus Erythematosus

  • CemdisiranALN-CC5Phase 35 trials

    Regeneron · Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, Age-related Macular Degeneration (AMD)

  • B007Phase 33 trials

    Shanghai Jiaolian Drug Research and Development Co., Ltd · Pemphigus, Primary Membranous Nephropathy, Generalized Myasthenia Gravis

  • KYV-101Phase 32 trials

    Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.